Planned sales, announced before they happen
1 trading plan running, 21 Form 144 notices for $44.2M
Plans running now
1
Robert F. Probst
What VTR's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Trading plans
Plans adopted or ended
| Insider | What | Date | Shares | Runs to | Reported in |
|---|---|---|---|---|---|
| Peter J. Bulgarelli Executive Vice President, Outpatient Medical and Research |
Adopted 10b5-1 plan | Feb 20, 2025 | up to 15,000 | Feb 20, 2026 | 10-Q May 1, 2025 |
What the company wroteOn February 20, 2025, Peter J. Bulgarelli, Executive Vice President, Outpatient Medical and Research of the Company and President and CEO of Lillibridge Healthcare Services, Inc., adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Bulgarelli’s trading plan is for the sale of up to 15,000 shares of our common stock in amounts and prices determined in accordance with a formula set forth in the plan and terminates on the earlier of the date all the shares under the plan are sold and February 20, 2026. | |||||
| Robert F. Probst Executive Vice President and Chief Financial Officer |
Adopted 10b5-1 plan | Feb 19, 2025 | up to 320,057 | Jan 15, 2027 | 10-Q May 1, 2025 |
What the company wroteOn February 19, 2025, Robert F. Probst, Executive Vice President and Chief Financial Officer of the Company, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Probst’s trading plan covers (i) the sale of an amount of shares of our common stock necessary to generate an aggregate of up to $4.6 million in net proceeds and (ii) the potential exercise and sale of up to 320,057 shares of our common stock with respect to expiring options, in each case in amounts and prices determined in accordance with a formula set forth in the plan, and terminates on the earlier of the date all the shares under the plan are sold and January 15, 2027. | |||||
| Walter C. Rakowich director |
Adopted 10b5-1 plan | Sep 15, 2024 | up to 1,459 | Jun 30, 2026 | 10-Q Oct 31, 2024 |
| Gregory R. Liebbe Chief Accounting Officer |
Adopted 10b5-1 plan | Aug 13, 2024 | up to 21,114 | Aug 10, 2025 | 10-Q Oct 31, 2024 |
What the company wroteOn August 13, 2024, Gregory R. Liebbe, Chief Accounting Officer of the Company, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Liebbe’s trading plan is with respect to his expiring options and covers the potential exercise and sale of up to 21,114 shares of our common stock in amounts and prices determined in accordance with a formula set forth in the plan and terminates on the earlier of the date all the shares under the plan are sold and August 10, 2025. | |||||
| Peter J. Bulgarelli Executive Vice President, Outpatient Medical & Research of the Company and President and CEO of Lillibridge Healthcare Services, Inc |
Adopted 10b5-1 plan | Mar 11, 2024 | up to 22,500 | 365 days | 10-Q May 2, 2024 |
What the company wroteOn March 11, 2024, Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research of the Company and President and CEO of Lillibridge Healthcare Services, Inc., adopted a new trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Bulgarelli’s trading plan is for the sale of up to 22,500 shares of our common stock in amounts and prices determined in accordance with a formula set forth in the plan and terminates on the earlier of the date all the shares under the plan are sold and March 11, 2025. | |||||
| Debra A. Cafaro Chairman and CEO of the Company |
Adopted 10b5-1 plan | – | up to 1,546,317 | 1023 days | 10-Q May 2, 2024 |
What the company wroteOn March 28, 2024, Debra A. Cafaro, Chairman and CEO of the Company, adopted a new trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Ms. Cafaro’s trading plan is with respect to her expiring options and covers the potential exercise and sale of up to 1,546,317 shares of our common stock in amounts and prices determined in accordance with a formula set forth in the plan and terminates on the earlier of the date all the shares under the plan are sold and January 15, 2027. | |||||
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 9, 2023.
Form 144
Notices of planned sales
| Filed | Seller | Shares | Value | Shares came from | 10b5-1 plan | Form 4 sales after |
|---|---|---|---|---|---|---|
| May 14, 2026 | Walter C. Rakowich Director |
1,152 | $104K | RSU grant | adopted Sep 15, 2024 | 1,152 shares from May 14, 2026 |
| Mar 2, 2026 | GREGORY LIEBBE Officer |
17,248 | $1.5M | ESOP | none given | none found |
| Feb 11, 2026 | CAREY SHEA ROBERTS Officer |
35,532 | $3.0M | Restricted stock vesting under a registered plan | none given | none found |
| Feb 6, 2026 | CAFARO DEBRA A Officer, Director |
10,322 | $849K | Exercise of employee stock options | adopted Mar 28, 2024 | none found |
| Feb 2, 2026 | CAFARO DEBRA A Officer, Director |
10,322 | $802K | Exercise of employee stock options | adopted Mar 28, 2024 | none found |
| Jan 2, 2026 | CAFARO DEBRA A Officer, Director |
10,322 | $797K | Exercise of employee stock options | adopted Mar 28, 2024 | none found |
| Jan 2, 2026 | Robert F Probst Officer |
29,930 | $2.3M | Vested RSU | adopted Feb 19, 2025 | none found |
| Dec 1, 2025 | CAFARO DEBRA A Officer, Director |
10,322 | $831K | Exercise of employee stock options | adopted Mar 28, 2024 | none found |
| Nov 19, 2025 | Bulgarelli Peter J. Executive Vice President |
2,229 | $179K | Compensation Shares | adopted Feb 20, 2025 | none found |
| Nov 18, 2025 | Bulgarelli Peter J. Executive Vice President |
2,771 | $222K | Compensation Shares | adopted Feb 20, 2025 | none found |
| Nov 17, 2025 | CAFARO DEBRA A Officer, Director |
41,294 | $3.3M | Exercise of employee stock options | adopted Mar 28, 2024 | none found |
| Nov 12, 2025 | Robert F Probst Officer |
33,591 | $2.6M | Exercise of employee stock options | adopted Feb 19, 2025 | none found |
| Nov 7, 2025 | Bulgarelli Peter J. Executive Vice President |
40 | $3K | Compensation Shares | adopted Feb 20, 2025 | none found |
| Nov 6, 2025 | Bulgarelli Peter J. Executive Vice President |
166 | $12K | Compensation Shares | adopted Feb 20, 2025 | none found |
| Nov 6, 2025 | CAFARO DEBRA A Officer, Director |
264 | $20K | Exercise of employee stock options | adopted Mar 28, 2024 | none found |
| Nov 5, 2025 | Bulgarelli Peter J. Executive Vice President |
870 | $65K | Compensation Shares | adopted Feb 20, 2025 | none found |
| Nov 5, 2025 | CAFARO DEBRA A Officer, Director |
19,250 | $1.4M | Exercise of employee stock options | adopted Mar 28, 2024 | none found |
| Nov 4, 2025 | Bulgarelli Peter J. Executive Vice President |
3,924 | $294K | Compensation Shares | adopted Feb 20, 2025 | none found |
| Nov 4, 2025 | CAFARO DEBRA A Officer, Director |
11,452 | $859K | Exercise of employee stock options | adopted Mar 28, 2024 | none found |
| Nov 3, 2025 | CAFARO DEBRA A Officer, Director |
20,644 | $1.5M | Exercise of employee stock options | adopted Mar 28, 2024 | none found |
| Oct 30, 2025 | CAFARO DEBRA A Officer, Director |
317,258 | $23.6M | Exercise of employee stock options | adopted Mar 28, 2024 | none found |
Show the other 13 notices
From the Form 144 XML filed with the SEC, since Oct 30, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.